BioSpace News Archive

AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced the appointment of Gail M. Farfel, Ph.D., to its Board of Directors.

STAAR Surgical Company, a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, announced that it will release financial results for the third quarter ended October 2, 2020 on Wednesday, November 4, 2020 after the market close.

Additional Analysis Shows Potential of Biktarvy to Be an Important Treatment Option for People Living With HIV Who are Virologically Suppressed and Have End Stage Renal Disease Requiring Hemodialysis

The Salk Institute and BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced a three-year collaboration agreement formed to advance cutting-edge academic discoveries in genetically driven diseases toward therapeutic applications.

The initiative of Ichilov Tel Aviv Sourasky Medical Center will bring together medical professionals from ten countries to develop concrete ideas for combatting issues pertaining to COVID-19

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that an abstract for the TRIDENT-1 clinical study of its lead drug candidate repotrectinib has been selected for a mini-oral presentation on Jan. 31, 2021 at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer.

Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that the company has entered into a license agreement with Nuance Biotech Co. Ltd (Nuance), a China based specialty pharmaceutical company, providing Nuance with the exclusive rights to develop and commercialize Neumentum’s novel ketorolac for IV infusion (NTM-001) in China. NTM-001, is a novel, alcohol-free formulati

Vir Biotechnology, Inc. (NASDAQ: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced the presentation of preclinical and Phase 1 data demonstrating the broad neutralizing ability, high-level effector function, extended half-life and tolerability of VIR-2482 in the prevention of influenza A

VolitionRx Limited a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, hosted a capital markets day event yesterday and releases a video of that event.

PLOS Medicine joins growing evidence of safe use of ibuprofen/Advil for COVID-19 symptoms